IndicationsHuidaGene has multiple R&D pipelines for neurology, ophthalmology and myology.
-
01Neurology Diseases
MECP2 Duplication Syndrome (MDS)
Huntington's Disease (HD)
Amyotrophic Lateral Sclerosis (ALS)
-
02Ophthalmology Diseases
RPE65 Mutation-Associated Inherited Retinal Dystrophies (IRDs)
Neovascular Age-related Macular Degeneration (nAMD)
RHO-Associated Retinitis Pigmentosa (RHO-adRP)
-
03Myology Diseases
-
HuidaGene Therapeutics to Attend BIO-Europe Fall Conference in Munich for Actively Expanding Global CollaborationNov 03,2023
Learn More
-
HuidaGene Therapeutics Announces First Patient Dosed in Multnational Phase 1/2 Trial of HG004 for Inherited BlindnessNov 02,2023
Learn More
-
U.S. FDA Awards Both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing Therapy, for the Treatment of MECP2 Duplication SyndromeOct 31,2023
Learn More